Building on Biomatlante’s core MBCP™ Technology, In’Oss™ is an innovative and moldable synthetic bone graft, composed of Hydroxyapatite (HA), Beta Tricalcium Phosphate (ß-TCP) and a hydrogel.
Developed to facilitate handling during bone grafting procedures, In’Oss™ can fit into different grafting sites.
In’Oss™, is the optimal balance between MBCP™ micro granules and an absorbable hydrogel, acting as a carrier for rapid vascularization and mineralization.
In’Oss™ keeps the original graft shape and bone volume. It is gradually absorbed to be replaced by vital architectured bone.
MBCP™ Technology’s Key Features
Provides a matrix for new bone growth
HA alone resorbs too slowly while TCP resorbs too fast. Bi-phasic HA and TCP allow for a resorption rate similar to that of human bone.
Interconnected network of macropores and micropores that enables the colonization of bone cells and biological fluid uniformly within the matrix.
For ionic exchange: TCP dissolution and bone crystal precipitation. Newly bioactive interface with bone cells.
Macropores are a network of interconnected spaces that promote the biological infiltration and cellular colonization by osteoblasts and osteoclasts.
Micropores are the intercrystalline spaces where dissolution and recrystallisation occurs.
Host bone formation is systematically demonstrated.
100% synthetic – 5 years shelf life.
2. Maxillary Sinus Bone Grafting with an Injectable Bone Substitute: a Sheep Study, A.Saffarzadeh, O. Gauthier, and al., Key Engineering Materials Vols. 254-256 (2004) p. 193-196
3. Tricalcium phosphate/hydroxyapatite biphasic calcium phosphate (BCP) bioceramics , in Bioceramics and theirs clinical applications, Daculsi G., LeGeros R., T. Kokubo editor, Woodhead publishing, 2008, pp 395-4242
4. A New Injectable Bone Substitute Concept (MBCP Gel ™): First Clinical Results in Human Maxillo-Facial Surgery, Pierre Weiss, Léon Philippe Clergeau, Bénédicte Enckel, Yves Amouriq, Bernard Giumelli, Alain Jean and Guy Daculsi, Key Engineering Materials Vols. 284-286 (2005) pp. 1053-1056
5. Five Years Clinical Follow up Bone Regeneration with CaP Bioceramics Clemencia Rodríguez, Alain Jean, and Guy Daculsi, Key Engineering Materials Vols. 361-363(2008) pp. 1339-1342
6. Assessment of Cancellous Bone Architecture after Implantation of an Injectable Bone Substitute, Catherine A. Davy, O. Gauthier, and al., Key Engineering Materials Vols. 254-256 (2004) pp. 55-5842
• Do not leave the defect opened
• In’Oss™ has to be in direct contact with at least 2 or 3 surfaces. Maximum contact between In’Oss™ and recipient bone must be achieved.
• In’Oss™ does not have initial mechanical properties and should not be used for load-bearing applications without independent rigid fixation or any kind of osteo synthetic stabilisation.
• Adequate post-operative immobilization is to be used to facilitate the osteogenesis.
• Post surgery discharge is necessary.
• Implantation is not recommended in revision surgery site containing non resorbable biomaterials residues.
• The product has not been tested on pregnant women. The risk of health has not been established.
- ISO 13485
- Read the instructions for use
- MBCP™ is supplied sterile and CE-marked as a Class III Medical Device according to Directive EEC/93/42
Is indicated augment or substitute for bone graft in nonloadbearing clinical applications
- Posterolateral Fusion